MTOR and anemia: In addition to nausea/vomiting and renal insufficiency, hypertension (in patients who received oral treatment and those treated with TK/VEGF inhibitors) and anemia (in patients who received IV treatment and those treated with mTOR-directed therapy) were among the four most common AEs when evaluated separately by treatment categories.